HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel
Portfolio Pulse from
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, highlighted a CNN program featuring Dr. David Feifel discussing ketamine. Kadima Neuropsychiatry Institute, founded by Dr. Feifel, is set to become HOPE's flagship clinic upon acquisition closure.
January 14, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NRx Pharmaceuticals, through its subsidiary HOPE Therapeutics, is involved in a potential acquisition of Kadima Neuropsychiatry Institute, which was featured in a CNN program on ketamine.
The feature on CNN increases visibility for NRx Pharmaceuticals and its subsidiary HOPE Therapeutics. The planned acquisition of Kadima Neuropsychiatry Institute as a flagship clinic could enhance NRx's market position in interventional psychiatry.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80